SCHEMBL4524149

SCHEMBL4524149

O=C1C(Cc2ccc(F)cc2Cl)CCN1C1CCc2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.43
MEN1 O00255 2/20 0.43
ALDH1A1 P00352 2/20 0.43
MAPT P10636 2/20 0.43
KMT2A Q03164 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD11B1 P28845 2/20 0.39
P2RX7 Q99572 10/20 0.38
GPR84 Q9NQS5 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
HPGD P15428 1/20 0.37
MAPK1 P28482 1/20 0.37
CYP2C19 P33261 1/20 0.37
AHR P35869 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4510847 0.90 SMN1; SMN2 (0.52) KDM4EMEN1ALDH1A1MAPTKMT2A
SCHEMBL4513609 0.88 KDM4E (0.42) KDM4EMEN1ALDH1A1MAPTKMT2A
SCHEMBL4526694 0.88 KDM4E (0.44) KDM4EMEN1ALDH1A1MAPTKMT2A
SCHEMBL4514845 0.87 KDM4E (0.46) KDM4EMEN1ALDH1A1MAPTKMT2A
SCHEMBL4510366 0.87 KDM4E (0.46) KDM4EMEN1ALDH1A1MAPTKMT2A
SCHEMBL4500555 0.87 CTSD (0.46) KDM4EMEN1ALDH1A1MAPTKMT2A
SCHEMBL4516442 0.86 ALDH1A1 (0.41) KDM4EMEN1ALDH1A1MAPTKMT2A
SCHEMBL4508542 0.83 HSD11B1 (0.42) KDM4EMEN1ALDH1A1MAPTKMT2A
SCHEMBL4523992 0.83 HSD11B1 (0.42) KDM4EMEN1ALDH1A1MAPTKMT2A
SCHEMBL4513256 0.83 HSD11B1 (0.42) KDM4EMEN1ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 KDM4E 2703/4885MEN1 1254/4885ALDH1A1 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.